TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21672497

Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: olanzapine + A (amantadine 200 mg/d with possible switches to metformin 1,000‐1,500 mg/d and then to zonisamide 100‐400 mg/d)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: olanzapine + B (metformin 1,000‐1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100‐400 mg/d)
Number of subjects: 199

Group type: COMPARATOR
Intervention: pooled results of olanzapine + A and olanzapine + B
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: olanzapine + B
Number of subjects: 199
Study: 20136825

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDara-C)
Number of subjects: 94
Study: 18768415

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (n = 175)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Sodium chloride (n = 178)
Number of subjects: 353
Study: 16086806

Group type: EXPERIMENTAL
Intervention: Support group participation
Number of subjects: 20
Study: 12881348

Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10378499

Group type: EXPERIMENTAL
Intervention: Cold stimulus (10 degrees C to 12 degrees C) for 10 seconds followed by a cold wetpack at the neck for 1 minute.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warm stimulus (34 degrees C to 36 degrees C) for the same duration.
Number of subjects: 24
Study: 8767942

Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional open surgery
Number of subjects: 20
Study: 1984813

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA) 50 to 100 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 6872413

Group type: EXPERIMENTAL
Intervention: 75 mg amrinone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 150 mg amrinone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 225 mg amrinone
Number of subjects: 18
Study: 31752954

Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MRI/US fusion-guided biopsy
Number of subjects: 600

Group type: COMPARATOR
Intervention: TRUS-only biopsy
Number of subjects: 600
Study: 29322972

Group type: EXPERIMENTAL
Intervention: Intraoperative lumbar subarachnoid drainage (LSAD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No lumbar drain insertion (no LSAD)
Number of subjects: 60
Study: 27009515

Group type: EXPERIMENTAL
Intervention: Ranibizumab 'intensive' treatment (complete resolution of IRF and SRF)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Ranibizumab 'relaxed' treatment (resolution of IRF or >200 μm SRF only at foveal centre)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Ranibizumab 'intensive' treatment
Number of subjects: 347

Group type: COMPARATOR
Intervention: Ranibizumab 'relaxed' treatment
Number of subjects: 347
Study: 26978207

Group type: EXPERIMENTAL
Intervention: Inhaled xenon combined with hypothermia (33°C) for 24 hours (n=55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hypothermia treatment alone (n=55)
Number of subjects: 110
Study: 22433613

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus regular moderate aerobic exercise (HDMAE)
Number of subjects: 32
Study: 20298591

Group type: EXPERIMENTAL
Intervention: 40 mg SC enoxaparin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 50 mg SC enoxaparin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 60 mg SC enoxaparin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 70 mg SC enoxaparin
Number of subjects: 72
Study: 18534276

Group type: EXPERIMENTAL
Intervention: Istaroxime 0.5 microg/kg/min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Istaroxime 1.0 microg/kg/min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Istaroxime 1.5 microg/kg/min
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15778562

Group type: EXPERIMENTAL
Intervention: Fall prevention program (40 minutes, once a week for 6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 12459658

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (1.8 g/kg, with an additional 0.9 g/kg dose if hemoglobin < 6.5 g/dl)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (PFC)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Control group (standard of care)
Number of subjects: 492
Study: 10347103

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10-12 mg/kg/d taken as a single bedtime dose
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 8551317

Group type: EXPERIMENTAL
Intervention: Propofol at subhypnotic doses
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1960304

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 6443090

Group type: EXPERIMENTAL
Intervention: Tubocurarine (5 mg dose)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tubocurarine (repeated 5 mg doses)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no tubocurarine)
Number of subjects: 23
Study: 29991076

Group type: EXPERIMENTAL
Intervention: Knee closure in flexion at 90°
Number of subjects: 75

Group type: COMPARATOR
Intervention: Knee closure in extension
Number of subjects: 75
Study: 28629270

Group type: EXPERIMENTAL
Intervention: Modified wheelchair arm-support for at least 60 minutes a day, six days a week, for four weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basic rehabilitation training and wheelchair assistance
Number of subjects: 120
Study: 26692037

Group type: EXPERIMENTAL
Intervention: Additional asthma education
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no additional asthma education)
Number of subjects: 88
Study: 24531810

Group type: EXPERIMENTAL
Intervention: 40 min of leg cycling (noncuffed exercise)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cuffed exercise
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Noncuffed exercise
Number of subjects: 21
Study: 23285026

Group type: EXPERIMENTAL
Intervention: Rubber hand illusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 20306820

Group type: EXPERIMENTAL
Intervention: Intravenous montelukast, 5.25 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 21514123

Group type: EXPERIMENTAL
Intervention: TJ‐29 (bakumondoto) for 2 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no TJ‐29) for 2 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (TJ‐29 and control)
Number of subjects: 19
Study: 15951475

Group type: EXPERIMENTAL
Intervention: Composite extended-release (ER) capsule (200 mg DP + 25 mg aspirin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional dipyridamole tablets (two 100 mg tablets + 81 mg aspirin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional dipyridamole tablets (immediate-release)
Number of subjects: 20
Study: 11807777

Group type: EXPERIMENTAL
Intervention: BRCA heterozygotes (6 BRCA1, 2 BRCA2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BRCA heterozygotes (8 BRCA1, 1 BRCA2)
Number of subjects: 8
Study: 9601159

Group type: EXPERIMENTAL
Intervention: Positive placebo suggestion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Negative placebo suggestion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 8273981

Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 1300 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 2600 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 3 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2647014

Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation
Number of subjects: 75
Study: 30043934

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-pregnant women)
Number of subjects: 60
Study: 27789385

Group type: EXPERIMENTAL
Intervention: Nocebo suggestions (suggestions of pain increase with nocebo cream)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo suggestions (suggestions of pain decrease with placebo cream)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural history group (no treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocebo group (suggestions of pain increase)
Number of subjects: 0
Study: 25909846

Group type: EXPERIMENTAL
Intervention: ABM combined with anodal tDCS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ABM combined with cathodal tDCS
Number of subjects: 3

Group type: COMPARATOR
Intervention: ABM combined with sham tDCS
Number of subjects: 3
Study: 22944550

Group type: EXPERIMENTAL
Intervention: Head positioned with a support
Number of subjects: 60

Group type: COMPARATOR
Intervention: Head positioned without a support
Number of subjects: 60
Study: 19819486

Group type: EXPERIMENTAL
Intervention: Massage and exercise programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo control (simulated magnetotherapy)
Number of subjects: 66
Study: 17975506

Group type: EXPERIMENTAL
Intervention: CO2 (30% v/v)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CO2 (40% v/v)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ethyl acetate (5.5% v/v)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ethyl acetate (9.3% v/v)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: acetic acid (205 v/v)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: acetic acid (40 v/v)
Number of subjects: 15

Group type: COMPARATOR
Intervention: All stimuli
Number of subjects: 15
Study: 16875159

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (267 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 35
Study: 12499050

Group type: EXPERIMENTAL
Intervention: C1r codon 135 polymorphism
Number of subjects: 0
Study: 11712441

Group type: EXPERIMENTAL
Intervention: Antiplatelet autoantibody occurrence determined by ELISA method
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Platelet morphological parameters evaluation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Megathrombocyte population evaluation
Number of subjects: 15
Study: 8829419

Group type: EXPERIMENTAL
Intervention: Incisional morphine 5 mg injected in the incision (10 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg (10 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine 5 mg (10 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline injected in the incision, 10 patients)
Number of subjects: 40
Study: 1625092

Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of hGH plus oxandrolone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall treatment with hGH (both alone and in combination with oxandrolone)
Number of subjects: 70
Study: 6548095

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of methohexitone (5 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rectal administration of methohexitone (25 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous administration of methohexitone (2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of pharmacokinetics in children vs adults
Number of subjects: 20
Study: 31750210

Group type: EXPERIMENTAL
Intervention: Inj Caroverine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba extract
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (Inj)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (extract)
Number of subjects: 86
Study: 30316811

Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (NLP)
Number of subjects: 36
Study: 25888661

Group type: EXPERIMENTAL
Intervention: Group I (n = 72) - provided information related to ultrasound findings and allowed to watch the procedures from the monitor
Number of subjects: 151

Group type: COMPARATOR
Intervention: Group II (n = 79) - received injection only without any collaboration
Number of subjects: 151
Study: 25319729

Group type: EXPERIMENTAL
Intervention: 30 mg/day aqueous saffron extract orally
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23007147

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 8 mg/m² (day 1) and Vinorelbine (VNR) 25 mg/m² (days 1 and 8) every 4 weeks for up to 6 cycles
Number of subjects: 51
Study: 19797535

Group type: EXPERIMENTAL
Intervention: Alvimopan with ciprofloxacin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Alvimopan without ciprofloxacin
Number of subjects: 45
Study: 17445831

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine XR 150 mg/day
Number of subjects: 0
Study: 15905675

Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (RTV) (300/100 mg or 600/100 mg twice daily, or 900/100 mg once daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (RTV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no change in PIs)
Number of subjects: 50
Study: 12506950

Group type: EXPERIMENTAL
Intervention: Fluconazole suspension 3 mg/kg in a single daily dose for 7 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nystatin oral suspension four times a day for 10 days
Number of subjects: 34
Study: 9883920

Group type: EXPERIMENTAL
Intervention: Medical termination
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Surgical termination
Number of subjects: 275

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 275
Study: 7569503

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2705441

Group type: EXPERIMENTAL
Intervention: Subcutaneous DDAVP
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous DDAVP
Number of subjects: 9
Study: 335794

Group type: EXPERIMENTAL
Intervention: Combination of thiazide and methyldopa (regimen A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Combination of beta-receptor blocker and hydralazine (regimen B)
Number of subjects: 28
Study: 30552937

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 181
Study: 27693959

Group type: EXPERIMENTAL
Intervention: Lateral wedge orthotics
Number of subjects: 109

Group type: COMPARATOR
Intervention: Neutral orthotics
Number of subjects: 109
Study: 25029662

Group type: EXPERIMENTAL
Intervention: 5,000-point group
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0-point group
Number of subjects: 0
Study: 23400616

Group type: EXPERIMENTAL
Intervention: Cogmed JM program (10-15 minutes a day, 5 days a week for 5 weeks)
Number of subjects: 20
Study: 21272821

Group type: EXPERIMENTAL
Intervention: DVD intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control (paper handouts)
Number of subjects: 137
Study: 19066876

Group type: EXPERIMENTAL
Intervention: Performance (Shaklee Corp.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gatorade
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 19
Study: 17373593

Group type: EXPERIMENTAL
Intervention: Paced learning trial (P)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-paced control (NP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HR feedback
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HR + RPE feedback
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: No feedback (CONT)
Number of subjects: 42
Study: 15382974

Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program (SCCIP) - a 4-session, 1-day intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study: 11441208

Group type: EXPERIMENTAL
Intervention: High-dose acetaminophen (1000 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-dose acetaminophen (500 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9097872

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8332152

Group type: EXPERIMENTAL
Intervention: Outpatient treatment with ceftriaxone (50 mg/kg body weight, initial dose followed by a second dose 24 hours later)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inpatient treatment (ceftriaxone as directed by physicians)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 86

Group type: COMPARATOR
Intervention: Higher-risk children treated as inpatients
Number of subjects: 86
Study: 3793953

Group type: COMPARATOR
Intervention: Chlorpropamide (C) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (C) with sucralfate (S)
Number of subjects: 12
Study: 30882476

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (colloid)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (crystalloid)
Number of subjects: 1057
Study: 27129476

Group type: EXPERIMENTAL
Intervention: Parenting in 2 Worlds (P2W)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Healthy Families in 2 Worlds (HF2W)
Number of subjects: 575
Study: 25155227

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 600
Study: 22244349

Group type: EXPERIMENTAL
Intervention: MMN-1
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: MMN-2
Number of subjects: 324

Group type: COMPARATOR
Intervention: IFA-2
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: MMN-1 and MMN-2
Number of subjects: 324
Study: 21246578

Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated surfaces)
Number of subjects: 20
Study: 17349686

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (1 x 10(8) colony forming units) daily from gestational week 36 until delivery and continued from birth until 12 months of age.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo group (not specified dosage or duration).
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri group.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo group.
Number of subjects: 188
Study: 16248382

Group type: EXPERIMENTAL
Intervention: Dynamic scans of thallium-201 (201Tl) scintigraphy
Number of subjects: 175
Study: 12960597

Group type: EXPERIMENTAL
Intervention: 201Tl‐chloride scintigraphy (early image)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 201Tl‐chloride scintigraphy (delayed image)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bone scintigraphy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Follow-up 201Tl‐chloride scintigraphy after chemotherapy
Number of subjects: 21
Study: 10824635

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion after pretreatment with nadolol or propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isoproterenol infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nadolol or propranolol (doses < or =40 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (doses < or =7.5 mg)
Number of subjects: 8
Study: 9238585

Group type: EXPERIMENTAL
Intervention: Population-Adjusted Clinical Epidemiology (PACE) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megatrial approach
Number of subjects: 0
Study: 1430708

Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate (L‐ASA) 900 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled sodium salicylate (equivalent dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (25 mg and 50 mg)
Number of subjects: 13
Study: 6539002

Group type: EXPERIMENTAL
Intervention: Stanozolol 50 mg intramuscularly 24 hr before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo intramuscularly
Number of subjects: 60
Study: 3524929

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 240 mg orally for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31337167

Group type: EXPERIMENTAL
Intervention: High-voltage, long-duration pulsed radiofrequency (PRF) at 42°C for 900 seconds
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham group (no radiofrequency energy output)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-voltage, long-duration pulsed radiofrequency (PRF)
Number of subjects: 96
Study: 29046302

Group type: COMPARATOR
Intervention: Tea administered simultaneously with the meal (TM-2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tea administered 1 hour postmeal (TM-3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water administered with the meal (TM-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of TM-2 and TM-3
Number of subjects: 12
Study: 25796146

Group type: EXPERIMENTAL
Intervention: Amlodipine combined with enalapril
Number of subjects: 114

Group type: COMPARATOR
Intervention: Amlodipine (control group)
Number of subjects: 114
Study: 24045528

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21208648

Group type: EXPERIMENTAL
Intervention: Penile circular skin graft (PCG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Penile skin flap (PCF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (PCG and PCF)
Number of subjects: 37